An evaluation of the use of a negative interferon-γ release assay for tuberculosis screening before TNF antagonist therapy

Eur Respir J. 2014 Nov;44(5):1369-72. doi: 10.1183/09031936.00125714. Epub 2014 Sep 3.

Authors

Georgia Woodfield¹, Benjamin Passey-Heaton², Anob Chakrabarti¹, Anton Pozniak³, Michael R Loebinger⁴

Affiliations

¹ Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
² St George's University of London, London, UK.
³ Chelsea and Westminster Hospital NHS Foundation Trust, London, UK Imperial College, London, UK.
⁴ Chelsea and Westminster Hospital NHS Foundation Trust, London, UK Imperial College, London, UK Royal Brompton and Harefield NHS Foundation Trust, London, UK m.loebinger@rbht.nhs.uk.

PMID: 25186258
DOI: 10.1183/09031936.00125714

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Adalimumab
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized / administration & dosage
Antitubercular Agents / administration & dosage
Etanercept
Humans
Immunoglobulin G / administration & dosage
Infliximab
Interferon-gamma Release Tests*
Latent Tuberculosis / diagnosis*
Latent Tuberculosis / drug therapy
Mass Screening / methods
Receptors, Tumor Necrosis Factor / administration & dosage
Registries
Retrospective Studies
Tuberculin Test*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antitubercular Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Infliximab
Adalimumab
Etanercept